Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has been given a $94.00 price objective by equities research analysts at Royal Bank Of Canada in a research report issued to clients and investors on Sunday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s target price points to a potential upside of 22.88% from the company’s current price.

A number of other research analysts have also weighed in on the company. BidaskClub lowered Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday. Zacks Investment Research upgraded Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, July 10th. Mizuho dropped their target price on Eagle Pharmaceuticals from $66.00 to $57.00 and set an “underperform” rating on the stock in a report on Thursday, May 25th. ValuEngine upgraded Eagle Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 16th. Finally, Piper Jaffray Companies set a $118.00 target price on Eagle Pharmaceuticals and gave the company an “overweight” rating in a report on Tuesday, May 9th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $90.00.

Eagle Pharmaceuticals (NASDAQ:EGRX) traded up 1.02% on Friday, hitting $76.50. The company’s stock had a trading volume of 243,934 shares. The stock has a market cap of $1.17 billion, a PE ratio of 12.02 and a beta of 1.48. Eagle Pharmaceuticals has a 12 month low of $42.33 and a 12 month high of $97.15. The firm has a 50 day moving average of $77.28 and a 200-day moving average of $77.94.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings results on Monday, May 8th. The specialty pharmaceutical company reported $1.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.44 by $0.02. The firm had revenue of $76.80 million during the quarter, compared to the consensus estimate of $70.10 million. Eagle Pharmaceuticals had a return on equity of 57.82% and a net margin of 29.85%. The firm’s revenue was up 159.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.06) EPS. On average, analysts expect that Eagle Pharmaceuticals will post $3.66 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Eagle Pharmaceuticals Inc (EGRX) Given a $94.00 Price Target at Royal Bank Of Canada” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/17/eagle-pharmaceuticals-inc-egrx-given-a-94-00-price-target-at-royal-bank-of-canada.html.

In other Eagle Pharmaceuticals news, CFO Pete A. Meyers purchased 350 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The shares were acquired at an average cost of $71.49 per share, for a total transaction of $25,021.50. Following the completion of the acquisition, the chief financial officer now owns 350 shares of the company’s stock, valued at approximately $25,021.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Proquest Investments Iv, L.P. sold 54,180 shares of Eagle Pharmaceuticals stock in a transaction on Tuesday, April 25th. The stock was sold at an average price of $88.38, for a total value of $4,788,428.40. The disclosure for this sale can be found here. Insiders have purchased 805 shares of company stock worth $61,790 over the last quarter. 19.50% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the company. BlackRock Inc. raised its stake in shares of Eagle Pharmaceuticals by 183,871.5% in the first quarter. BlackRock Inc. now owns 1,206,853 shares of the specialty pharmaceutical company’s stock worth $100,097,000 after buying an additional 1,206,197 shares during the period. Victory Capital Management Inc. raised its stake in shares of Eagle Pharmaceuticals by 24.3% in the first quarter. Victory Capital Management Inc. now owns 1,072,714 shares of the specialty pharmaceutical company’s stock worth $88,971,000 after buying an additional 209,398 shares during the period. JW Asset Management LLC raised its stake in shares of Eagle Pharmaceuticals by 1.1% in the fourth quarter. JW Asset Management LLC now owns 857,679 shares of the specialty pharmaceutical company’s stock worth $76,050,000 after buying an additional 8,970 shares during the period. BlackRock Fund Advisors raised its stake in shares of Eagle Pharmaceuticals by 87.0% in the third quarter. BlackRock Fund Advisors now owns 769,869 shares of the specialty pharmaceutical company’s stock worth $53,891,000 after buying an additional 358,134 shares during the period. Finally, Iridian Asset Management LLC CT raised its stake in shares of Eagle Pharmaceuticals by 1,804.5% in the first quarter. Iridian Asset Management LLC CT now owns 755,027 shares of the specialty pharmaceutical company’s stock worth $62,622,000 after buying an additional 715,382 shares during the period.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.